Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma
Burkitt lymphoma is a highly aggressive subtype of non-Hodgkin lymphoma. And it is one of the fastest growing human tumors. The lymphoma can be divided into three subclasses: endemic type, sporadic type and immunodeficiency-associated type, according to epidemiology and different miRNA profiles. The...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-02-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0818.htm |
| _version_ | 1819172247345037312 |
|---|---|
| author | SUN Yuanyuan ZHANG Mingzhi |
| author_facet | SUN Yuanyuan ZHANG Mingzhi |
| author_sort | SUN Yuanyuan |
| collection | DOAJ |
| description | Burkitt lymphoma is a highly aggressive subtype of non-Hodgkin lymphoma. And it is one of the fastest growing human tumors. The lymphoma can be divided into three subclasses: endemic type, sporadic type and immunodeficiency-associated type, according to epidemiology and different miRNA profiles. The disease is often found in children and teenagers, rarely in the adults. Outcome with short and intensive chemotherapy is excellent. But the prognosis is poor in adults who are in later period and resistant to therapy. PI3K/AKT/mTOR signaling pathway plays an important role in kinds of cellular functions, including growing, differentiation, metabolism, survival and proliferation. Studies have shown that the PI3K/AKT/mTOR signaling pathway is activated in Burkitt lymphoma, and the inhibitors of this pathway inhibit Burkitt lymphoma cells. We understand the pathogenesis of Burkitt lymphoma by exploring the effects and interaction of PTEN, c-Myc, autophagy and PI3K/AKT/mTOR signaling pathway. And we will manage the combination of PI3K/AKT/mTOR signaling pathway inhibitors with monoclonal antibodies or other pathway inhibitors to find accurate, effective and low-toxic targeted therapy for the adults with drug resistance or in later period. |
| first_indexed | 2024-12-22T20:04:09Z |
| format | Article |
| id | doaj.art-bfda2862a0c7449a8778532d74e909ec |
| institution | Directory Open Access Journal |
| issn | 1000-8578 1000-8578 |
| language | zho |
| last_indexed | 2024-12-22T20:04:09Z |
| publishDate | 2019-02-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-bfda2862a0c7449a8778532d74e909ec2022-12-21T18:14:11ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782019-02-0146216917310.3971/j.issn.1000-8578.2019.18.08188578.2019.18.0818Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt LymphomaSUN Yuanyuan0ZHANG Mingzhi1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, ChinaBurkitt lymphoma is a highly aggressive subtype of non-Hodgkin lymphoma. And it is one of the fastest growing human tumors. The lymphoma can be divided into three subclasses: endemic type, sporadic type and immunodeficiency-associated type, according to epidemiology and different miRNA profiles. The disease is often found in children and teenagers, rarely in the adults. Outcome with short and intensive chemotherapy is excellent. But the prognosis is poor in adults who are in later period and resistant to therapy. PI3K/AKT/mTOR signaling pathway plays an important role in kinds of cellular functions, including growing, differentiation, metabolism, survival and proliferation. Studies have shown that the PI3K/AKT/mTOR signaling pathway is activated in Burkitt lymphoma, and the inhibitors of this pathway inhibit Burkitt lymphoma cells. We understand the pathogenesis of Burkitt lymphoma by exploring the effects and interaction of PTEN, c-Myc, autophagy and PI3K/AKT/mTOR signaling pathway. And we will manage the combination of PI3K/AKT/mTOR signaling pathway inhibitors with monoclonal antibodies or other pathway inhibitors to find accurate, effective and low-toxic targeted therapy for the adults with drug resistance or in later period.http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0818.htmburkitt lymphomapi3k/akt/mtor signaling pathwayptenc-mycautophagytargeted therapy |
| spellingShingle | SUN Yuanyuan ZHANG Mingzhi Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma Zhongliu Fangzhi Yanjiu burkitt lymphoma pi3k/akt/mtor signaling pathway pten c-myc autophagy targeted therapy |
| title | Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma |
| title_full | Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma |
| title_fullStr | Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma |
| title_full_unstemmed | Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma |
| title_short | Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma |
| title_sort | research progress on pi3k akt mtor signaling pathway in burkitt lymphoma |
| topic | burkitt lymphoma pi3k/akt/mtor signaling pathway pten c-myc autophagy targeted therapy |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0818.htm |
| work_keys_str_mv | AT sunyuanyuan researchprogressonpi3kaktmtorsignalingpathwayinburkittlymphoma AT zhangmingzhi researchprogressonpi3kaktmtorsignalingpathwayinburkittlymphoma |